We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+75.99%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.76B
AUM Growth
+$607M
Cap. Flow
+$235M
Cap. Flow %
13.41%
Top 10 Hldgs %
43.13%
Holding
124
New
28
Increased
25
Reduced
20
Closed
29

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$34.5M
2
CYTK icon
Cytokinetics
CYTK
+$28M
3
VTYX
Ventyx Biosciences
VTYX
+$19.1M
4
ROIV icon
Roivant Sciences
ROIV
+$17.8M
5
FBRX icon
Forte Biosciences
FBRX
+$17.3M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$66.7M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$56.3M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$42.8M
4
MRUS
Merus
MRUS
+$26.9M
5
SLNO
Soleno Therapeutics
SLNO
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 76.68%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OBIO icon
76
Orchestra BioMed
OBIO
$225M
$2.38M 0.14%
572,804
-154,468
-21% -$623K
EPRX
77
Eupraxia Pharmaceuticals
EPRX
$413M
$2.27M 0.13%
300,000
– –
GERN icon
78
Geron
GERN
$930M
$1.98M 0.11%
1,500,000
– –
RARE icon
79
Ultragenyx Pharmaceutical
RARE
$2.88B
$1.73M 0.1%
+75,000
New +$2.47M
LENZ
80
PUT
LENZ Therapeutics
LENZ
$158M
$1.6M 0.09%
+100,000
New +$2.91M
KZR
81
DELISTED
Kezar Life Sciences
KZR
$1.44M 0.08%
+229,076
New +$1.34M
CMPS
82
Compass Pathways
CMPS
$1.6B
$1.38M 0.08%
200,000
– –
QURE icon
83
uniQure
QURE
$2.77B
$1.2M 0.07%
50,000
-250,000
-83% -$9.65M
CATX icon
84
Perspective Therapeutics
CATX
$333M
$825K 0.05%
300,000
– –
MGNX icon
85
MacroGenics
MGNX
$278M
$780K 0.04%
+484,308
New +$761K
PCSC
86
Perceptive Capital Solutions
PCSC
$128M
$652K 0.04%
50,000
-300,000
-86% -$3.5M
FBRX icon
87
CALL
Forte Biosciences
FBRX
$991M
$611K 0.03%
+22,400
New +$393K
XFOR icon
88
X4 Pharmaceuticals
XFOR
$345M
$580K 0.03%
+145,000
New +$527K
QTTB icon
89
Q32 Bio
QTTB
$339M
$92.2K 0.01%
27,777
– –
ADGM
90
Adagio Medical Holdings
ADGM
$11.1M
$83.2K ﹤0.01%
80,000
– –
RCKTW icon
91
Rocket Pharmaceuticals Warrant
RCKTW
$320K
$1.82K ﹤0.01%
75,000
– –
AKBA icon
92
Akebia Therapeutics
AKBA
$343M
– –
-2,450,000
Closed -$6.69M
ATXS
93
DELISTED
Astria Therapeutics
ATXS
– –
-300,000
Closed -$2.18M
AUTL
94
Autolus Therapeutics
AUTL
$378M
– –
-1,750,000
Closed -$2.85M
CNTX icon
95
Context Therapeutics
CNTX
$56.4M
– –
-402,653
Closed -$390K
ELVN icon
96
Enliven Therapeutics
ELVN
$3.74B
– –
-400,000
Closed -$8.19M
EXEL icon
97
CALL
Exelixis
EXEL
$14.1B
– –
-150,000
Closed -$6.2M
EXEL icon
98
PUT
Exelixis
EXEL
$14.1B
– –
-350,000
Closed -$14.5M
CBIO
99
Crescent Biopharma
CBIO
$531M
– –
-17,998
Closed -$214K
INSM icon
100
CALL
Insmed
INSM
$23.6B
– –
-205,000
Closed -$29.5M
1 2 3
4
5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q4 2025 Portfolio in Review

As of Q4 2025, Affinity Asset Advisors held 124 positions worth $1.76B, up 53% from $1.15B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Affinity Asset Advisors deployed $235M of net new capital in Q4 2025, opening 28 new positions and adding to 25 existing holdings. Its largest new stake was Praxis Precision Medicines: 185,000 shares worth $54.5M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 85% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $42.8M trimmed.

  • Affinity Asset Advisors's largest Q4 2025 buy was Praxis Precision Medicines: 185,000 shares worth $54.5M.
  • Affinity Asset Advisors added most to Cytokinetics in Q4 2025, an estimated $28M increase.
  • Affinity Asset Advisors's biggest Q4 2025 reduction was Madrigal Pharmaceuticals, cutting an estimated $42.8M.
  • Affinity Asset Advisors fully exited Verona Pharma in Q4 2025, selling an estimated $66.7M.
  • Affinity Asset Advisors's ten largest holdings make up 43% of its $1.76B portfolio in Q4 2025.
  • Affinity Asset Advisors opened 28 new positions and closed 29 in Q4 2025.
  • Affinity Asset Advisors's portfolio value rose 53% quarter-over-quarter to $1.76B.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.